These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24247812)

  • 1. A pharmacokinetic and pharmacodynamic comparison of immediate-release metoprolol and extended-release metoprolol CR/XL in patients with suspected acute myocardial infarction: a randomized, open-label study.
    Karlson BW; Dellborg M; Gullestad L; Aberg J; Sugg J; Herlitz J
    Cardiology; 2014; 127(2):73-82. PubMed ID: 24247812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
    Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-related effects of metoprolol on heart rate and pharmacokinetics in heart failure.
    Andersson B; Aberg J; Lindelöw B; Täng MS; Wikstrand J
    J Card Fail; 2001 Dec; 7(4):311-7. PubMed ID: 11782853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
    Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
    Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.
    Udelson JE; Pressler SJ; Sackner-Bernstein J; Massaro J; Ordronneau P; Lukas MA; Hauptman PJ
    J Card Fail; 2009 Jun; 15(5):385-93. PubMed ID: 19477398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses.
    Lücker P; Moore G; Wieselgren I; Olofsson B; Bergstrand R
    J Clin Pharmacol; 1990 Feb; 30(S2):S17-27. PubMed ID: 2312775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study.
    Wiklund O; Hulthe J; Wikstrand J; Schmidt C; Olofsson SO; Bondjers G
    Stroke; 2002 Feb; 33(2):572-7. PubMed ID: 11823672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF).
    Wikstrand J; Hjalmarson A; Waagstein F; Fagerberg B; Goldstein S; Kjekshus J; Wedel H;
    J Am Coll Cardiol; 2002 Aug; 40(3):491-8. PubMed ID: 12142116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.
    Deedwania PC; Giles TD; Klibaner M; Ghali JK; Herlitz J; Hildebrandt P; Kjekshus J; Spinar J; Vitovec J; Stanbrook H; Wikstrand J;
    Am Heart J; 2005 Jan; 149(1):159-67. PubMed ID: 15660048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure.
    Aquilante CL; Terra SG; Schofield RS; Pauly DF; Hatton PS; Binkley PF; Johnson JA
    J Card Fail; 2006 Apr; 12(3):171-6. PubMed ID: 16624680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence, pharmacokinetic and pharmacodynamic response to combined extended release formulations of felodipine and metoprolol in healthy volunteers.
    Aberg J; Abrahamsson B; Grind M; Nyberg G; Olofsson B
    Eur J Clin Pharmacol; 1997; 52(6):471-7. PubMed ID: 9342583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).
    Lancet; 1999 Jun; 353(9169):2001-7. PubMed ID: 10376614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evolution of oral drug forms of metoprolol: advantages of long acting modified release forms with modified release].
    Leonova MV; Maneshina OA; Belousov IuB
    Kardiologiia; 2010; 50(12):79-83. PubMed ID: 21591398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study.
    Goldstein S; Fagerberg B; Hjalmarson A ; Kjekshus J; Waagstein F; Wedel H; Wikstrand J;
    J Am Coll Cardiol; 2001 Oct; 38(4):932-8. PubMed ID: 11583861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets.
    Sandberg A; Blomqvist I; Jonsson UE; Lundborg P
    Eur J Clin Pharmacol; 1988; 33 Suppl():S9-14. PubMed ID: 3371395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF.
    Jánosi A; Ghali JK; Herlitz J; Czuriga I; Klibaner M; Wikstrand J; Hjalmarson A;
    Am Heart J; 2003 Oct; 146(4):721-8. PubMed ID: 14564329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
    Batty JA; Hall AS; White HL; Wikstrand J; de Boer RA; van Veldhuisen DJ; van der Harst P; Waagstein F; Hjalmarson Å; Kjekshus J; Balmforth AJ;
    Clin Pharmacol Ther; 2014 Mar; 95(3):321-30. PubMed ID: 24193112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic comparison of a new controlled-release formulation of metoprolol with a traditional slow-release formulation.
    Oosterhuis B; Jonkman JH; Kerkhof FA
    Eur J Clin Pharmacol; 1988; 33 Suppl():S15-8. PubMed ID: 3371389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF).
    Gottlieb SS; Fisher ML; Kjekshus J; Deedwania P; Gullestad L; Vitovec J; Wikstrand J;
    Circulation; 2002 Mar; 105(10):1182-8. PubMed ID: 11889011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation.
    Bialer M; Shekh-Ahmad T; Braun TL; Halvorsen MB
    Epilepsia; 2013 Aug; 54(8):1444-52. PubMed ID: 23692553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.